Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043693 | 0.97 | PTGDR2 (0.48) | CNR2SLC6A9PTGDR2CXCR5PDE4A | |
| SCHEMBL16961586 | 0.89 | CXCR5 (0.43) | CNR2SLC6A9PTGDR2CXCR5PDE4A | |
| SCHEMBL943472 | 0.85 | CNR2 (0.48) | CNR2SLC6A9CXCR5PDE4B | |
| SCHEMBL23287020 | 0.82 | MAP3K5 (0.42) | SLC6A9PTGDR2CXCR5 | |
| SCHEMBL29825320 | 0.82 | MAP3K5 (0.42) | SLC6A9PTGDR2CXCR5 | |
| SCHEMBL26388239 | 0.81 | CNR2 (0.44) | CNR2SLC6A9PTGDR2 | |
| SCHEMBL26388243 | 0.81 | GSK3B (0.45) | CNR2SLC6A9PTGDR2 | |
| SCHEMBL944838 | 0.79 | CYP11B2 (0.39) | CNR2SLC6A9PTGDR2 | |
| SCHEMBL24371188 | 0.79 | HCRTR1 (0.44) | CNR2SLC6A9 | |
| SCHEMBL24371182 | 0.78 | GPR6 (0.43) | CNR2SLC6A9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3026046-A1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | AbbVie Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2376462-B1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8895592-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2376462-A1 | Thiazoles as cannabinoid receptor ligands | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010071783-A1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2142522-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121558-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | CNR2 1/4885SLC6A9 4235/4885PTGDR2 4/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885SLC6A9 1623/4885PTGDR2 31/4885 |
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CNR2 2/4885SLC6A9 3420/4885PTGDR2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.